News & Updates

Show Multimedia Only

Timing of chemo during pregnancy may affect congenital malformation risk

10 Aug 2021 by

Exposure to chemotherapy in the first 12 weeks of pregnancy may be associated with an increased risk of major congenital malformations in offspring, a recent study showed.

Timing of chemo during pregnancy may affect congenital malformation risk

10 Aug 2021

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

07 Aug 2021

Use of cetuximab in combination with afatinib for the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutation does not appear to improve outcomes as compared with afatinib alone, according to the results of a phase II trial.

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

07 Aug 2021

Has COVID-19 changed the pathological outcomes in prostate cancer?

05 Aug 2021 by

The likelihood of pT3* or higher tumours and node-positive disease found at the time of radical prostatectomy (RP) for prostate cancer (PCa) was greater during the COVID-19 pandemic than it was before, an expert reported at EAU21.

Has COVID-19 changed the pathological outcomes in prostate cancer?

05 Aug 2021

News & Updates

Showing Oncology articles

Showing

Specialty:

Timing of chemo during pregnancy may affect congenital malformation risk

Timing of chemo during pregnancy may affect congenital malformation risk

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

Has COVID-19 changed the pathological outcomes in prostate cancer?

Has COVID-19 changed the pathological outcomes in prostate cancer?